Sironax Funding, Investors & Competitors

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.

Heyuan Biotechnology is a Chinese provider of gene therapy services, specializing in AAV and lentiviral vector production, CRISPR-based gene editing, and in vivo efficacy testing. Operating from facilities certified under ISO 13485, it supports pharma clients with plasmid design, viral packaging at titers exceeding 10^13 vg/mL, and animal model studies for CNS and oncology targets.

ArsenalBio is a South San Francisco-based, clinical-stage cell therapy company that engineers CAR T-cell therapies using CRISPR-based genome editing and logic-gating technology. Its pipeline targets solid tumors including ovarian, kidney, and prostate cancers, with its lead candidate, AB-2100, in Phase 1/2 trials for clear-cell renal cell carcinoma under a collaboration with Bristol-Myers Squibb. The platform is designed to address T-cell exhaustion, tumor specificity, and genome toxicity, challenges that have limited CAR T therapies in solid tumors.

Formation Bio is a South San Francisco-based biotechnology firm accelerating drug development through optimized clinical trials. It partners with pharma companies like Eli Lilly to redesign trial operations, leveraging technology for faster patient recruitment and data management in oncology and rare diseases.

Immunai is a biotechnology company with locations in New York City, San Francisco, and Tel Aviv, mapping the immune system using single-cell genomics and machine learning. The firm profiles hundreds of immune cell types from blood samples via its proprietary database, aiding biomarker discovery for therapeutics in autoimmune diseases and cancer.

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Merck KGaA operates in three main segments: life science, electronics, and healthcare. The life science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck family publicly sold part of the company, resulting in the current 30% public ownership of the firm.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Illumina is a genomics company headquartered in San Diego, California, that develops and sells DNA sequencing and array-based systems for research, clinical and applied markets. It was incorporated in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik and Mark Chee, and its shares trade on the Nasdaq under the symbol ILMN. Its NovaSeq, NextSeq and MiSeq sequencers and microarrays are bought by genomic research centers, pharmaceutical companies, academic institutions and clinical laboratories. Revenue comes from instrument sales and from the consumables and services used with an installed base of about 21,000 systems in 165 countries. Fiscal 2025 revenue was $4.34 billion, flat on 2024, with GAAP net income of $850 million, and the company has about 8,600 employees. It acquired the cancer-detection company GRAIL in 2021 and completed its spin-off in June 2024, keeping a 14.5% minority stake. In January 2025 it invested $20 million in Truveta alongside Regeneron to support the Truveta Genome Project.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Institut Mérieux is a family-owned healthcare holding company based in Lyon, France, controlled by the Mérieux family and focused on fighting infectious diseases and cancers. It is the majority shareholder of four companies: bioMérieux, a publicly listed world leader in in-vitro diagnostics; Mérieux NutriSciences, a food safety and nutrition testing and consulting provider; Transgene, a listed biotech developing therapeutic vaccines and oncolytic viruses against cancer; and Mérieux Equity Partners, a growth and innovation capital firm for healthcare and nutrition. Together the group employs about 26,000 people in more than 50 countries, and Institut Mérieux also holds strategic stakes in Ceva Animal Health and OXB. Its companies earn revenue from diagnostic instruments and reagents, laboratory testing and contract services sold to hospitals, laboratories, food producers and pharmaceutical companies. Institut Mérieux was founded in Lyon in 1897 by Marcel Mérieux, who had worked at the Institut Pasteur; it created bioMérieux in 1963, divested its vaccine business in 1994 and formed Mérieux NutriSciences in 2010. In July 2022 Exor, the Agnelli family's holding company, agreed to invest €833 million for a 10% stake through a reserved capital increase, adding John Elkann and Benoît Ribadeau-Dumas to the board. The company is led by chief executive Michel Baguenault.

Color is a health technology platform delivering population genomics, cancer screening, and COVID-19 testing programs for employers, schools, and governments. Headquartered in Burlingame, California, it processes whole-genome sequencing through CLIA-certified labs and partners with health systems like Kaiser Permanente for nationwide deployment.

Inari is a West Lafayette-headquartered biotechnology company developing seed traits through multiplex gene editing and predictive design via its SEEDesign platform. The firm targets corn, soybean, and wheat improvements for yield, drought tolerance, and nitrogen use efficiency. Founded in 2016, Inari operates greenhouses and field trial sites across the US Midwest and Brazil. It collaborates with Corteva and Bayer on commercialization pipelines for hybrid varieties suited to diverse climates.

Enveda Biosciences is a Mountain View-based biotechnology firm using AI to map chemical structures from natural sources for drug discovery. The company has built a database of over 1 million molecules from plants, microbes, and marine organisms, analyzed via mass spectrometry and machine learning. Enveda targets inflammation, oncology, and metabolic diseases, partnering with pharmaceutical companies like Bristol Myers Squibb for lead optimization.

BGI Group is a Shenzhen-headquartered global leader in genomics, operating as Shenzhen Huada Gene Technology Co. Ltd. The company delivers DNA sequencing, bioinformatics testing, genetic analysis, agricultural genomics, and proteomics services. With operations centered in China and international labs, it contributed to the Human Genome Project and advances precision medicine worldwide.

Sangon Biotech is a Shanghai-based biotechnology firm specializing in nucleic acid synthesis and molecular biology products. Founded in 2003 as a Sino-foreign joint venture, it manufactures DNA/RNA oligonucleotides, gene synthesis services, peptides, enzymes, reagents, lab consumables, and benchtop instruments. The company operates a production base in Songjiang Industrial Park, serving research institutions and pharmaceutical companies worldwide.

Everly Health, formerly Everlywell, is an Austin, Texas-based digital health company founded in 2015 by Julia Cheek. It provides at-home health testing kits for conditions including thyroid issues, allergies, and food sensitivities, alongside a digital health platform and virtual care offerings, and added FDA-authorized at-home COVID-19 collection kits in 2020. The company has expanded into enterprise partnerships with employers and health plans alongside its consumer testing business.

Everlywell is an Austin, Texas-based digital health company, founded in 2015, that sells at-home lab testing kits for conditions including cholesterol, thyroid health, fertility, testosterone, food sensitivities, and sexually transmitted infections, with results reviewed by physicians through partnered labs. The company added COVID-19 sample collection kits in March 2020, scaling to handle up to 250,000 tests per week during the pandemic. Its direct-to-consumer model combines e-commerce sales of test kits with lab fees, physician review, and subscription revenue for repeat testing.